GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Investments And Advances

Veru (STU:FMW) Investments And Advances : €0.21 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Veru Investments And Advances?

Veru's Investments And Advances for the quarter that ended in Jun. 2024 was €0.21 Mil.

Veru's quarterly Investments And Advances declined from Dec. 2023 (€0.49 Mil) to Mar. 2024 (€0.32 Mil) and declined from Mar. 2024 (€0.32 Mil) to Jun. 2024 (€0.21 Mil).


Veru Investments And Advances Historical Data

The historical data trend for Veru's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Investments And Advances Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Veru Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.49 0.32 0.21

Veru Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Veru Business Description

Industry
Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru Headlines

No Headlines